Resumen
Platin-based chemotherapy with pemetrexed has been the backbone of meaningful treatment in pleural mesothelioma for the last 16 years, alongside vinorelbine and gemcitabine, which show only modest response. Recently, a nivolumab and ipilimumab combination was approved, and it offers improvement in survival rate and quality of life. With the identification and understanding of novel biomarkers, many treatment options are currently being evaluated.